Advertisement

 

 

ICD Placement Doesn’t Improve Survival in Patients With CKD

ICD Placement Doesn’t Improve Survival in Patients With CKD
Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

THURSDAY, Feb. 8, 2018 (HealthDay News) — For implantable cardioverter defibrillator (ICD)-eligible patients with chronic kidney disease (CKD), ICD placement does not improve survival, according to a study published online Feb. 5 in JAMA Internal Medicine.

Nisha Bansal, M.D., from the University of Seattle, and colleagues examined the correlation of primary prevention ICDs with the risk of death and hospitalization in a cohort study including adults with heart failure and a left ventricular ejection fraction of 40 percent or less. Patients who received an ICD were matched in a 1-to-3 ratio with those who did not receive an ICD on CKD status, age, and high-dimensional propensity score to receive an ICD (1,556 with and 4,321 without an ICD).

The researchers found that there was no difference in all-cause mortality for patients with CKD in the ICD versus the non-ICD group in models adjusted for demographics, comorbidity, and cardiovascular medication use (adjusted hazard ratio, 0.96; 95 percent confidence interval, 0.87 to 1.06). Among patients with CKD, ICD placement was correlated with an increased risk of subsequent hospitalization due to heart failure (adjusted relative risk, 1.49; 95 percent confidence interval, 1.33 to 1.6) and any-cause hospitalization (adjusted relative risk, 1.25; 95 percent confidence interval, 1.2 to 1.3).

“The potential risks and benefits of ICDs should be carefully considered in patients with heart failure and CKD,” the authors write.

Abstract/Full Text (subscription or payment may be required)

Copyright © 2018 HealthDay. All rights reserved.
healthday

Submit a Comment

Your email address will not be published. Required fields are marked *

13 + five =

[ HIDE/SHOW ]